Overview

Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients

Status:
Recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of DAC combined with HAAG regimen in the induction treatment of newly diagnosed AML patients younger than 60 years.
Phase:
Phase 3
Details
Lead Sponsor:
The First Affiliated Hospital of Soochow University
Collaborators:
Changzhou No.2 People's Hospital
Huai'an Second People's Hospital
Jingjiang People's Hospital
Second Affiliated Hospital of Soochow University
The First People's Hospital of Lianyungang
The Third People's Hospital of Kunshan
Zhangjiagang First People's Hospital
Treatments:
Cytarabine
Decitabine
Idarubicin